정밀의료 시장 규모, 점유율, 동향 분석 보고서 : 용도별, 최종 용도별, 지역별, 부문별 예측(2024-2030년)

Precision Medicine Market Size, Share & Trends Analysis Report By Application (Diagnostics, Therapeutics), By End-use, By Region, And Segment Forecasts, 2024 - 2030

US $ 5,950 ￦ 8,158,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,529,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,271,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

정밀의료 시장 성장과 동향

Grand View Research, Inc.의 최신 보고서에 따르면, 세계 정밀의료 시장 규모는 2030년까지 2,492억 4,000만 달러에 달할 것이며, 2024년부터 2030년까지 연평균 16.3%의 성장률을 기록할 것으로 성장할 것으로 예상됩니다.

비용 효율적인 유전체 및 분자생물학적 검사법의 도입, 암 및 희귀질환의 유병률 증가, 정밀의료 분야에서의 빅데이터 활용 증가 등이 시장 성장을 견인하는 주요 요인으로 꼽힙니다.

인간 유전체 프로젝트는 전장 유전체 염기서열 분석, 표적 염기서열 분석과 같은 놀라운 첨단 기술을 도입했습니다. 이러한 기술은 연구자들이 유전체 연구와 다양한 질병 치료를 위한 맞춤형 치료법을 개발하기 위해 사용되고 있습니다. 오늘날 종양학, 면역학, 신경학 등 분야의 질병 유행은 전 세계적으로 빠르게 증가하고 있습니다.

연구자, 의료 전문가, 대형 제약회사 및 생명공학 회사들은 환자의 건강을 위해 새로운 치료 옵션을 찾기 위해 협력하고 있습니다. 현재 다양한 종류의 암을 치료하기 위해 많은 치료법과 약물이 임상시험 중에 있습니다. 또한, 연구자들은 암 이외의 질병 영역에서 정밀 의약품과 진단법 개발에도 관심을 보이고 있습니다.

치료와는 별도로 진단 분야도 최근 몇 년 동안 급성장하고 있습니다. 차세대 염기서열 분석(NGS), 바이오마커, 동반진단, 난해한 검사의 사용은 의약품 처방 패턴을 바꾸고 영향을 미칠 수 있습니다. 개인 맞춤형 의약품은 향후 20년 내에 큰 성공을 거둘 가능성이 매우 높으며, 이전에는 불가능했던 소수의 난치병을 치료하고 치유할 수 있는 능력을 가지고 있습니다.

정부와 규제기관의 참여는 이 분야의 성장에 매우 중요한 역할을 하고 있으며, 2015년 당시 미국 정부는 정밀의료 이니셔티브의 출범을 발표했습니다. 이듬해 중국은 '중국 정밀의료 이니셔티브'를 출범시켰습니다. 이는 15년 계획으로, 중국을 정밀치료 개발의 선두 국가로 만드는 것을 목표로 하고 있습니다.

현재 생명공학기업과 제약기업의 개선 파이프라인에 있는 약품의 40% 이상이 바이오마커를 포함하고 있습니다. 이 개요는 지난 5년간 여러 바이오 제약사들이 공동사업과 합작투자를 진행했으며, 향후 몇 년 동안 계속될 것으로 예상한다고 밝혔습니다. 이처럼 진단 및 치료용 정밀의료 시장은 엄청난 잠재력을 가지고 있으며, 환자 치료의 기본 분야로 빠르게 변모하고 있습니다.

정밀의료 시장 보고서 하이라이트

• 2023년에는 치료제 분야가 시장을 주도했으며, 예측 기간 동안 15.8%의 CAGR로 성장할 것으로 예상됩니다.
• 병원 분야는 2023년 60.0%의 매출 점유율로 시장을 선도했습니다. 병원은 종합적인 인프라와 다양한 환자 집단에 대한 접근성으로 인해 개인 맞춤형 의료에 이상적인 환경을 제공합니다.
• 2023년 북미 정밀의료 시장은 53.62%의 점유율을 차지했으며, PMC의 2022년 보고서에 따르면 2014년 이후 FDA가 승인한 의약품 4개 중 1개 이상이 개인맞춤형 의약품으로 나타났다고 합니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 정밀의료 시장 변수, 동향, 범위

• 시장 계통 전망
  • 상부 시장 전망
  • 관련/부수 시장 전망
• 시장 역학
  • 시장 견인 요인 분석
  • 시장 성장 억제요인 분석
• 시장 기회 분석
• 정밀의료 시장 분석 툴
  • 업계 분석 - Porter's Five Forces 분석
  • PESTEL 분석
  • 가격 분석
  • 수량 분석(기기)

제4장 정밀의료 시장 : 용도 추정·동향 분석

• 세계의 정밀의료 시장 : 용도 대시보드
• 세계의 정밀의료 시장 : 용도 변동 분석
• 세계의 정밀의료 시장 : 용도별, 매출별
• 진단
• 치료

제5장 정밀의료 시장 : 최종 용도 추정·동향 분석

• 세계의 정밀의료 시장 : 최종 용도 대시보드
• 세계의 정밀의료 시장 : 최종 용도 변동 분석
• 세계의 정밀의료 시장 : 최종 용도별, 매출별
• 재택 케어
• 병원
• 임상 검사실
• 기타

제6장 정밀의료 시장 : 카테고리, 용도, 최종 용도, 조사 방법별 지역 추정·동향 분석

• 지역 대시보드
• 시장 규모, 예측 동향 분석, 2018-2030년
• 북미
• 유럽
• 아시아태평양
• 라틴아메리카
• 중동 및 아프리카

제7장 경쟁 상황

• 주요 시장 진출 기업에 의한 최근의 동향과 영향 분석
• 기업/경쟁 분류
• 벤더 상황
  • 주요 유통업체 및 채널 파트너 리스트
  • 주요 고객
  • 주요 기업의 시장 점유율 분석, 2023년
  • F. Hoffmann-La Roche Ltd
  • Siemens Healthineers AG
  • Janssen Global Services, LLC
  • Illumina, Inc.
  • Quest Diagnostics Incorporated
  • 23andMe, Inc.
  • NeoDiagnostix
  • Myriad Genetics
  • Medtronic
  • GE Healthcare
  • Abbott
  • QIAGEN

ksm

영문 목차

영문목차

Precision Medicine Market Growth & Trends:

The global precision medicine market size is expected to reach USD 249.24 billion by 2030 growing at a CAGR of 16.3% from 2024 to 2030, according to a new report by Grand View Research, Inc. Trends such as introduction of cost-effective genomic and molecular biology testing methods, increasing prevalence of cancer and rare diseases, and rising use of big data in precision medicine are some of the key factors boosting market growth.

The Human Genome Project introduced some marvelous cutting-edge techniques such as whole genome sequencing and targeted sequencing. These technologies are being used by researchers for the study of genomes and creation of personalized therapies for treatment of various illnesses. Today, the prevalence of diseases in areas such as oncology, immunology, and neurology has rapidly increased across the globe.

Researchers, healthcare professionals, and big pharma and biotech companies are working together to recognize new focused treatments options for the wellbeing of patients. Currently, there are many therapies and drugs under clinical trials for treatment of different types of cancers. Moreover, researchers have also shown an inclination toward development of precision medicines and diagnostics in non-oncologic disease areas.

Apart from therapeutics, the diagnostics field has also witnessed rapid growth in the past few years. The use of next generation sequencing (NGS), biomarkers, companion diagnostics, and esoteric tests can possibly change and affect prescription patterns of pharmaceutical medicines. Personalized medicines have very high chances of becoming a massive success in the next 20 years and have the capacity to treat and cure a few obstinate illnesses, which was not possible before.

Involvement of government and regulatory bodies has played a very important role in the growth of this field. In 2015, the then U.S. government announced the launch of the Precision Medicine Initiative. The following year, China launched the China Precision Medicine Initiative, which is a 15-year project that aims to build the country as a leader in development of precision therapies.

At present, more than 40% of the medications in biotech and pharmaceutical companies' improvement pipeline incorporate biomarkers. The overview likewise recommended that some biopharmaceutical organizations have collaborated and joint their ventures in the past five years and are expected to continue doing so in the coming years. The diagnostic and therapeutic precision medicine market thus holds immense potential and is quickly turning into a fundamental segment of patient care.

Precision Medicine Market Report Highlights:

• The therapeutics segment led the market in 2023 and is expected to grow at a CAGR of 15.8% over the forecast period.
• The hospitals segment led the market with a revenue share of 60.0% in 2023. Hospitals provide the ideal setting for personalized medicine due to their comprehensive infrastructure and access to diverse patient populations.
• The North America precision medicine market accounted for 53.62% share in 2023. PMC report published in 2022 notes that personalized medicines now account for more than one in four drugs approved by the FDA since 2014.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Application
  • 1.2.2. End-use
  • 1.2.3. Regional scope
  • 1.2.4. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Application and End-use outlook
  • 2.2.2. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Precision Medicine Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Technological advancements in next-generation sequencing
    • 3.2.1.2. Expanding portfolio of companion/associated diagnostics
    • 3.2.1.3. Increasing prevalence of cancer & usage of biomarkers for precision medicine cancer therapy
    • 3.2.1.4. Growing healthcare expenditure triggering development of effective precision medicine
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Presence of nonvalue-based precision medicine diagnostics reimbursement policy
    • 3.2.2.2. Lack of proper intellectual property regulations for precision medical technologies
    • 3.2.2.3. Nonstructural development of biomarkers
• 3.3. Market opportunity analysis
  • 3.3.1.1. Advancements in genomic technologies
• 3.4. Precision Medicine Market Analysis Tools
  • 3.4.1. Industry Analysis - Porter's
    • 3.4.1.1. Supplier power
    • 3.4.1.2. Buyer power
    • 3.4.1.3. Substitution threat
    • 3.4.1.4. Threat of new entrant
    • 3.4.1.5. Competitive rivalry
  • 3.4.2. PESTEL Analysis
    • 3.4.2.1. Political landscape
    • 3.4.2.2. Technological landscape
    • 3.4.2.3. Economic landscape
  • 3.4.3. Pricing Analysis
  • 3.4.4. Volume Analysis (Instruments)

Chapter 4. Precision Medicine Market: Application Estimates & Trend Analysis

• 4.1. Global Precision Medicine Market: Application Dashboard
• 4.2. Global Precision Medicine Market: Application Movement Analysis
• 4.3. Global Precision Medicine Market by Application, Revenue
• 4.4. Diagnostics
  • 4.4.1. Diagnostics market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.2. Genetic Testing
    • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.3. Direct to Consumer Tests
    • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.4. Esoteric Tests
    • 4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.5. Others
    • 4.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Therapeutics
  • 4.5.1. Therapeutics market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5.2. Pharmaceuticals
    • 4.5.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.2.2. Oncology
    • 4.5.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.2.3. Respiratory Disease
    • 4.5.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.2.4. Skin Diseases
    • 4.5.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.2.5. CNS Disorders
    • 4.5.2.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.2.6. Immunology
    • 4.5.2.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.2.7. Genetic Diseases
    • 4.5.2.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.2.8. Others
    • 4.5.2.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5.3. Medical Devices
    • 4.5.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5.4. Others
    • 4.5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Precision Medicine Market: End-use Estimates & Trend Analysis

• 5.1. Global Precision Medicine Market: End-use Dashboard
• 5.2. Global Precision Medicine Market: End-use Movement Analysis
• 5.3. Global Precision Medicine Market by End-use, Revenue
• 5.4. Home care
  • 5.4.1. Home care market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. Hospitals
  • 5.5.1. Hospitals market estimates and forecasts 2018 to 2030 (USD Million)
• 5.6. Clinical Laboratories
  • 5.6.1. Clinical Laboratories market estimates and forecasts 2018 to 2030 (USD Million)
• 5.7. Others
  • 5.7.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Precision Medicine Market: Regional Estimates & Trend Analysis by Category, Application, End-use and Methodology

• 6.1. Regional Dashboard
• 6.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 6.3. North America
  • 6.3.1. U.S.
    • 6.3.1.1. Key country dynamics
    • 6.3.1.2. Regulatory framework/ reimbursement structure
    • 6.3.1.3. Competitive scenario
    • 6.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.3.2. Canada
    • 6.3.2.1. Key country dynamics
    • 6.3.2.2. Regulatory framework/ reimbursement structure
    • 6.3.2.3. Competitive scenario
    • 6.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.3.3. Mexico
    • 6.3.3.1. Key country dynamics
    • 6.3.3.2. Regulatory framework/ reimbursement structure
    • 6.3.3.3. Competitive scenario
    • 6.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 6.4. Europe
  • 6.4.1. UK
    • 6.4.1.1. Key country dynamics
    • 6.4.1.2. Regulatory framework/ reimbursement structure
    • 6.4.1.3. Competitive scenario
    • 6.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.2. Germany
    • 6.4.2.1. Key country dynamics
    • 6.4.2.2. Regulatory framework/ reimbursement structure
    • 6.4.2.3. Competitive scenario
    • 6.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.3. France
    • 6.4.3.1. Key country dynamics
    • 6.4.3.2. Regulatory framework/ reimbursement structure
    • 6.4.3.3. Competitive scenario
    • 6.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.4. Italy
    • 6.4.4.1. Key country dynamics
    • 6.4.4.2. Regulatory framework/ reimbursement structure
    • 6.4.4.3. Competitive scenario
    • 6.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.5. Spain
    • 6.4.5.1. Key country dynamics
    • 6.4.5.2. Regulatory framework/ reimbursement structure
    • 6.4.5.3. Competitive scenario
    • 6.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.6. Norway
    • 6.4.6.1. Key country dynamics
    • 6.4.6.2. Regulatory framework/ reimbursement structure
    • 6.4.6.3. Competitive scenario
    • 6.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.7. Sweden
    • 6.4.7.1. Key country dynamics
    • 6.4.7.2. Regulatory framework/ reimbursement structure
    • 6.4.7.3. Competitive scenario
    • 6.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.8. Denmark
    • 6.4.8.1. Key country dynamics
    • 6.4.8.2. Regulatory framework/ reimbursement structure
    • 6.4.8.3. Competitive scenario
    • 6.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 6.5. Asia Pacific
  • 6.5.1. Japan
    • 6.5.1.1. Key country dynamics
    • 6.5.1.2. Regulatory framework/ reimbursement structure
    • 6.5.1.3. Competitive scenario
    • 6.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.2. China
    • 6.5.2.1. Key country dynamics
    • 6.5.2.2. Regulatory framework/ reimbursement structure
    • 6.5.2.3. Competitive scenario
    • 6.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.3. India
    • 6.5.3.1. Key country dynamics
    • 6.5.3.2. Regulatory framework/ reimbursement structure
    • 6.5.3.3. Competitive scenario
    • 6.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.4. Australia
    • 6.5.4.1. Key country dynamics
    • 6.5.4.2. Regulatory framework/ reimbursement structure
    • 6.5.4.3. Competitive scenario
    • 6.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.5. South Korea
    • 6.5.5.1. Key country dynamics
    • 6.5.5.2. Regulatory framework/ reimbursement structure
    • 6.5.5.3. Competitive scenario
    • 6.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.6. Thailand
    • 6.5.6.1. Key country dynamics
    • 6.5.6.2. Regulatory framework/ reimbursement structure
    • 6.5.6.3. Competitive scenario
    • 6.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 6.6. Latin America
  • 6.6.1. Brazil
    • 6.6.1.1. Key country dynamics
    • 6.6.1.2. Regulatory framework/ reimbursement structure
    • 6.6.1.3. Competitive scenario
    • 6.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.2. Argentina
    • 6.6.2.1. Key country dynamics
    • 6.6.2.2. Regulatory framework/ reimbursement structure
    • 6.6.2.3. Competitive scenario
    • 6.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 6.7. MEA
  • 6.7.1. South Africa
    • 6.7.1.1. Key country dynamics
    • 6.7.1.2. Regulatory framework/ reimbursement structure
    • 6.7.1.3. Competitive scenario
    • 6.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.2. Saudi Arabia
    • 6.7.2.1. Key country dynamics
    • 6.7.2.2. Regulatory framework/ reimbursement structure
    • 6.7.2.3. Competitive scenario
    • 6.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.3. UAE
    • 6.7.3.1. Key country dynamics
    • 6.7.3.2. Regulatory framework/ reimbursement structure
    • 6.7.3.3. Competitive scenario
    • 6.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.4. Kuwait
    • 6.7.4.1. Key country dynamics
    • 6.7.4.2. Regulatory framework/ reimbursement structure
    • 6.7.4.3. Competitive scenario
    • 6.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Recent Developments & Impact Analysis, By Key Market Participants
• 7.2. Company/Competition Categorization
• 7.3. Vendor Landscape
  • 7.3.1. List of key distributors and channel partners
  • 7.3.2. Key customers
  • 7.3.3. Key company market share analysis, 2023
  • 7.3.4. F. Hoffmann-La Roche Ltd
    • 7.3.4.1. Company overview
    • 7.3.4.2. Financial performance
    • 7.3.4.3. Product benchmarking
    • 7.3.4.4. Strategic initiatives
  • 7.3.5. Siemens Healthineers AG
    • 7.3.5.1. Company overview
    • 7.3.5.2. Financial performance
    • 7.3.5.3. Product benchmarking
    • 7.3.5.4. Strategic initiatives
  • 7.3.6. Janssen Global Services, LLC
    • 7.3.6.1. Company overview
    • 7.3.6.2. Financial performance
    • 7.3.6.3. Product benchmarking
    • 7.3.6.4. Strategic initiatives
  • 7.3.7. Illumina, Inc.
    • 7.3.7.1. Company overview
    • 7.3.7.2. Financial performance
    • 7.3.7.3. Product benchmarking
    • 7.3.7.4. Strategic initiatives
  • 7.3.8. Quest Diagnostics Incorporated
    • 7.3.8.1. Company overview
    • 7.3.8.2. Financial performance
    • 7.3.8.3. Product benchmarking
    • 7.3.8.4. Strategic initiatives
  • 7.3.9. 23andMe, Inc.
    • 7.3.9.1. Company overview
    • 7.3.9.2. Financial performance
    • 7.3.9.3. Product benchmarking
    • 7.3.9.4. Strategic initiatives
  • 7.3.10. NeoDiagnostix
    • 7.3.10.1. Company overview
    • 7.3.10.2. Financial performance
    • 7.3.10.3. Product benchmarking
    • 7.3.10.4. Strategic initiatives
  • 7.3.11. Myriad Genetics
    • 7.3.11.1. Company overview
    • 7.3.11.2. Financial performance
    • 7.3.11.3. Product benchmarking
    • 7.3.11.4. Strategic initiatives
  • 7.3.12. Medtronic
    • 7.3.12.1. Company overview
    • 7.3.12.2. Financial performance
    • 7.3.12.3. Product benchmarking
    • 7.3.12.4. Strategic initiatives
  • 7.3.13. GE Healthcare
    • 7.3.13.1. Company overview
    • 7.3.13.2. Financial performance
    • 7.3.13.3. Product benchmarking
    • 7.3.13.4. Strategic initiatives
  • 7.3.14. Abbott
    • 7.3.14.1. Company overview
    • 7.3.14.2. Financial performance
    • 7.3.14.3. Product benchmarking
    • 7.3.14.4. Strategic initiatives
  • 7.3.15. QIAGEN
    • 7.3.15.1. Company overview
    • 7.3.15.2. Financial performance
    • 7.3.15.3. Product benchmarking
    • 7.3.15.4. Strategic initiatives

관련자료